Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2018, it had three operating cord blood banks in the Beijing municipality, the Guangdong province, and the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation is a subsidiary of Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (Limited Partnership).
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorMedical
Phone852-3605-8180
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$149.34 million
Profitability
Miscellaneous
Employees1,196
Next Earnings Date6/25/2019 (Estimated)
OptionableOptionable
Global Cord Blood (NYSE:CO) Frequently Asked Questions
What is Global Cord Blood's stock symbol?
Global Cord Blood trades on the New York Stock Exchange (NYSE) under the ticker symbol "CO."
How often does Global Cord Blood pay dividends? What is the dividend yield for Global Cord Blood?
Global Cord Blood announced an annual dividend on Tuesday, June 26th. Investors of record on Monday, July 30th will be paid a dividend of $0.08 per share on Monday, August 20th. This represents a yield of 0.93%. The ex-dividend date of this dividend is Friday, July 27th. View Global Cord Blood's Dividend History.
How were Global Cord Blood's earnings last quarter?
Global Cord Blood Corp (NYSE:CO) issued its earnings results on Tuesday, June, 26th. The medical research company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.13 by $0.09. The medical research company had revenue of $37.14 million for the quarter. Global Cord Blood had a net margin of 23.64% and a return on equity of 7.10%. View Global Cord Blood's Earnings History.
When is Global Cord Blood's next earnings date?
Has Global Cord Blood been receiving favorable news coverage?
News stories about CO stock have been trending somewhat positive recently, according to InfoTrie. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Global Cord Blood earned a news impact score of 0.7 on InfoTrie's scale. They also assigned media headlines about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days.
Who are some of Global Cord Blood's key competitors?
Some companies that are related to Global Cord Blood include Intercept Pharmaceuticals (ICPT), Aphria (APHA), Ansell (ANN), Merit Medical Systems (MMSI), Allogene Therapeutics (ALLO), BTG (BTG), Neogen (NEOG), ASPEN PHARMACAR/ADR (APNHY), Amicus Therapeutics (FOLD), EBOS Group (EBO), Evotec (EVT), MorphoSys (MOR), Tenet Healthcare (THC), Global Blood Therapeutics (GBT) and GETINGE AB/ADR (GNGBY).
What other stocks do shareholders of Global Cord Blood own?
Who are Global Cord Blood's key executives?
Global Cord Blood's management team includes the folowing people:
- Ms. Ting Zheng, Chairman, CEO & Interim CEO of Beijing Division (Age 47)
- Mr. Albert Chen, CFO & Director (Age 43)
- Ms. Xin Xu, Chief Technology Officer (Age 65)
- Ms. Rui Arashiyama, Chief Exec. Officer of Guangdong Division & Zhejiang Division (Age 60)
- Ms. Cathy Bai, VP of Corp. Fin.
Who are Global Cord Blood's major shareholders?
Global Cord Blood's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Norges Bank (0.53%), Quinn Opportunity Partners LLC (0.21%), PEAK6 Investments LLC (0.09%), Two Sigma Advisers LP (0.05%), Two Sigma Investments LP (0.04%) and California Public Employees Retirement System (0.04%). View Institutional Ownership Trends for Global Cord Blood.
Which institutional investors are selling Global Cord Blood stock?
CO stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Two Sigma Advisers LP, Quinn Opportunity Partners LLC and California Public Employees Retirement System. View Insider Buying and Selling for Global Cord Blood.
Which institutional investors are buying Global Cord Blood stock?
How do I buy shares of Global Cord Blood?
Shares of CO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Global Cord Blood's stock price today?
One share of CO stock can currently be purchased for approximately $6.99.
How big of a company is Global Cord Blood?
Global Cord Blood has a market capitalization of $849.64 million and generates $149.34 million in revenue each year. Global Cord Blood employs 1,196 workers across the globe.
What is Global Cord Blood's official website?
How can I contact Global Cord Blood?
Global Cord Blood's mailing address is 48 FL. BANK OF CHINA TOWER 1 GARDEN ROAD, HONG KONG K3, . The medical research company can be reached via phone at 852-3605-8180 or via email at [email protected]
MarketBeat Community Rating for Global Cord Blood (NYSE CO)
MarketBeat's community ratings are surveys of what our community members think about Global Cord Blood and other stocks. Vote "Outperform" if you believe CO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CO will underperform the S&P 500 over the long term. You may vote once every thirty days.
